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Abstract
Background: Toll-like receptors enable the host to recognize a large number of pathogen-
associated molecular patterns such as bacterial lipopolysaccharide, viral RNA, CpG-containing
DNA and flagellin. Toll-like receptors have also been shown to play a pivotal role in both innate
and adaptive immune responses. The role of Toll-like receptors as a primary part of our microbe
defense system has been shown in several studies, but their possible function as mediators in allergy
and asthma remains to be established. The present study was designed to examine the expression
of Toll-like receptors 2, 3 and 4 in the nasal mucosa of patients with intermittent allergic rhinitis,
focusing on changes induced by exposure to pollen.
Methods: 27 healthy controls and 42 patients with seasonal allergic rhinitis volunteered for the
study. Nasal biopsies were obtained before and during pollen season as well as before and after
allergen challenge. The seasonal material was used for mRNA quantification of Toll-like receptors
2, 3 and 4 with real-time polymerase chain reaction, whereas specimens achieved in conjunction
with allergen challenge were used for immunohistochemical localization and quantification of
corresponding proteins.
Results: mRNA and protein representing Toll-like receptors 2, 3 and 4 could be demonstrated in
all specimens. An increase in protein expression for all three receptors could be seen following
allergen challenge, whereas a significant increase of mRNA only could be obtained for Toll-like
receptor 3 during pollen season.
Conclusion: The up-regulation of Toll-like receptors 2, 3 and 4 in the nasal mucosa of patients
with symptomatic allergic rhinitis supports the idea of a role for Toll-like receptors in allergic
airway inflammation.
Background
Toll-like receptors (TLRs) have recently emerged as key
receptors of the innate immune system. They recognize
specific pathogen-associated molecular patterns initiating
a host defense response [1]. The upper airway encounters
potential pathogens like bacteria and viruses in inspired
air, and the discovery of TLRs on epithelial cells suggests
that the epithelium has a role in the mucosal immune
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system [2-4]. Activation of TLR-dependent signaling path-
ways results in the expression of effector molecules, such
as cytokines and chemokines, which contributes to the
activation of the antigen-specific adaptive immune
response [5]. The discovery that microbial components
and endogenous ligands are recognized by TLRs may
explain how generated signals can affect the initiation,
maintenance and progression of inflammatory diseases
[6]. Several authors have recently suggested a role for TLRs
in the pathophysiology of allergic rhinitis and asthma,
thus indicating the importance to study their expression
during allergic airway inflammation [7,8].
Ten distinct TLRs have been described in humans,
expressed in various combinations in cells of the immune
system as well as in other cell types [9,10]. mRNA of all
ten TLRs has been described in human nasal airway tissue,
but protein verification using Western blot analysis or
immunohistochemistry is still lacking for most TLRs in
the nose [2,11]. In cultured airway epithelial cells, mRNA
and corresponding proteins have been demonstrated for
TLR2, TLR3, TLR4 and TLR5 [4,12-14]. TLR2 has also been
demonstrated in the lower respiratory tract using immu-
nohistochemistry and both TLR2 and TLR4 have been
shown in alveolar epithelial cells with real-time PCR and
flow cytometry [15,16]. No difference in the sinonasal
mRNA expression of TLR2 and TLR4 could be demon-
strated when patients with chronic sinusitis and/or nasal
polyps were compared with healthy controls [3]. In
another study, TLR4 immunoreactivity was detected in
nasal mucosa from both children and adults irrespective
of atopy status, revealing a higher expression level among
children [17].
The present study was designed to quantify mRNA and
protein expressions of TLR2, TLR3 and TLR4 in the nasal
mucosa of patients with seasonal allergic rhinitis, before
and after pollen exposure, and to compare these findings
with data derived from healthy volunteers.
Methods
Skin prick test
Skin prick tests (SPTs) were performed with a standard
panel of 10 common airborne allergens (ALK, Copenha-
gen, Denmark) including pollen (birch, timothy and
artemisia), house dust mites (D. Pteronyssimus and D. Fari-
nae), molds (Cladosporium and Alternaria) and animal
allergens (cat, dog and horse). SPTs were performed on
the volar side of the forearm with saline buffer as negative
and histamine chloride (10 mg/ml) as positive control.
The wheal reactions were measured after 20 min and des-
ignated as 4+, 3+, 2+, 1+ or 0 depending on the size in
relation to histamine and saline [18].
Subjects
The study included 42 patients (22 women) with sympto-
matic birch and/or grass pollen induced intermittent aller-
gic rhinitis and 27 healthy volunteers (13 women),
serving as controls. The median (range) age of patients
and controls was 36 (18–68) and 27 (16–50) years,
respectively. All control patients were healthy and the
same goes for the rhinitis patients, with the exception of
their allergy. None of the participants were subjected to
any other type of surgery than the nasal biopsy described
in the research protocol.
The diagnosis of birch and grass pollen induced allergic
rhinitis was based on a positive history of intermittent
allergic rhinitis for at least 2 years and a positive SPT to
birch and/or timothy pollen. All patients were classified as
having moderate to severe symptoms (itchy nose and
eyes, sneezing, nasal secretion and nasal blockage) during
birch and/or grass pollen season and they had all been
treated with antihistamines and nasal steroids, often in
combination with antihistamine or cromoglycate eye
drops, during pollen seasons previous years. Patients had
no symptoms of asthma at the time of visit and they did
not take any asthma medication (short or long acting β-
agonists and inhaled steroids). All patients presented 3+
or 4+ reactions towards birch or timothy in SPT. 13
patients presented positive reactions towards both birch
and timothy and 5 patients were in addition positive for
mugworth. Patients presenting positive reactions towards
animals (4 towards cat, 2 towards dog and 2 towards
horse), did not have any regular animal contact. Exclusion
criteria included a history of perennial symptoms, upper
airway infection during the last 2 weeks before the time of
visit and treatment with local or systemic corticosteroids
during the last 2 months. Occasional use of antihista-
mines was accepted.
The controls were all symptom-free, had no history of
allergic rhinitis and had negative SPTs to the standard
panel of allergens described above They had no history of
upper airway infection during the last 2 weeks before the
time of visit and they were all free of medication. Before
inclusion, all subjects, patients as well as controls, were
evaluated by an ear-, nose- and throat-consultant per-
forming nasoscopy. Individuals with signs or symptoms
of chronic rhinitis, hypertrophy of turbinates, septum
deviation, nasal polyposis or recurrent sinusitis were
excluded. None of the participants had been subjected to
any form of nasal or sinus surgery before inclusion in the
study. The study was approved by the Ethics Committee of
the Medical Faculty, Lund University.
Study design
Nasal biopsies for mRNA analysis were obtained from 12
patients with symptomatic seasonal allergic rhinitis,Respiratory Research 2005, 6:100 http://respiratory-research.com/content/6/1/100
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during either birch pollen (5 patients) or grass pollen sea-
son (7 patients). They were included when they had expe-
rienced substantial symptoms of rhinoconjunctivitis
(itchy nose and eyes, sneezing, nasal secretion and nasal
blockage) during at least 3 consecutive days. The majority
of the patients were seen within 5–10 days after the first
appearance of symptoms. A local pollen count confirmed
the presence of the relevant pollen in the air during this
period. In addition, 19 patients were seen before the pol-
len season and 18 healthy controls were sampled either
before or during the pollen season.
Nasal biopsies for immunohistochemistry were obtained
from 11 patients at two separate occasions outside pollen
season. The first biopsy was obtained during control con-
ditions without any form of challenge. 2–4 weeks later the
same patients were challenged intranasally with relevant
pollen. 24 hours after this challenge a second biopsy was
obtained. Only one biopsy was taken from each nostril.
Patients were challenged with 10,000 SQ/U per nostril of
Aquagen (ALK, Denmark) with either birch (3 patients) or
grass pollen (8 patients). 9 controls were sampled during
the same period.
Nasal biopsy procedure
Biopsies were taken from the inferior turbinate after topi-
cal application of local anesthesia containing lidocainhy-
drochloride/nafazoline (34 mg/mL/0.17 mg/mL) for 20
minutes. Biopsies were in total obtained from 69 different
individuals. The nasal biopsies were approximately 2 × 2
× 2 mm large and too small to be divided without losing
their morphology. As a consequence, material for mRNA
characterization and immunohistochemistry could not be
obtained from the same biopsy.
RNA extraction and reverse transcription
Nasal biopsies for mRNA extraction were immediately
placed in RNA-later (QIAGEN) for 24 hours and then fro-
zen. RNA was extracted from homogenized nasal biopsies
using the RNeasy Mini Kit (QIAGEN GmbH) according to
the supplier's protocol. All samples were treated with
DNase (QIAGEN). Total RNA quantity and quality were
assessed by a spectrophotometer and the wavelength
absorption ratio (260/280 nm) was between 1.8 and 2.0
in all preparations. Reverse transcription to cDNA was car-
ried out with Omniscript™ reverse transcriptase kit (QIA-
GEN GmbH) with oligo-dT primer in a final volume of 20
µl using the Mastercycler personal PCR machine (Eppen-
dorf AG, Germany), at 37°C for 1 hour.
Quantitative real-time PCR
Quantitative real-time PCR assays were performed using
the SmartCyclerII system (Cepheid, USA). Two different
types of PCR assays were used, each with a different pro-
tocol according to the manufacturer's recommendations.
For detection of TLR2 and β-actin, intron over-spanning
oligonucleotide primers were designed (Table I) using
Prime Express® 2.0 software (Applied Biosystems, USA)
and synthesized by DNA Technology A/S (Aarhus, Den-
mark). PCR was performed using QuantiTect™SYBR®
Green PCR kit (QIAGEN) in a final volume of 25 µl. Reac-
tions were incubated at 95°C for 15 min, then incubated
46 cycles at 94°C for 30 s followed by 55°C for 60 s (ini-
tially 65°C, followed by 2°C decrease the first 6 cycles).
Standard curves for TLR2 and β-actin were prepared using
half 10log dilutions of PCR products generated from target
cDNA. Specific PCR products were analyzed by running
melting curves. Melting curve analysis for TLR2 and β-
actin revealed a single peak in each sample.
For detection of TLR3, TLR4 and β-actin, primers were
purchased from Applied Biosystems. These PCR assays
contained a probe and were performed using Taq-
Man®Universal PCR Master Mix NoAmpErase®UNG in a
final volume of 25 µl. Reactions were incubated at 95°C
for 10 min, then incubated 40 cycles at 95°C for 15 s fol-
lowed by 60°C for 60 s. When using a probe as in these
PCR assays, nonspecific amplification is not detected.
Gene expression changes were assessed using the compar-
ative cycle threshold (CT) method http://docs.appliedbio
systems.com/pebiodocs/04303859.pdf. The relative
amount of mRNA for TLR2, TLR3 and TLR4 was deter-
mined by subtracting the CT values achieved for these
genes from the CT value of the housekeeping gene β-actin.
The amount of mRNA is expressed in relation to 100,000
mRNA molecules of β-actin (100,000 × 2-∆CT).
Immunohistochemical analysis of TLRs
Nasal biopsies used for immunohistochemistry were fro-
zen in Tissue Tek® O.C.T mounting media (Histo Lab,
Gothenburg, Sweden) immediately after excision. Cryo-
sections, 8 µm thick, were after sectioning post-fixed with
2% buffered formaldehyde for 20 min, rinsed in phos-
phate buffered saline (PBS; pH 7.6; 3 × 5 min at room
temperature (RT)) and placed in 0.1% saponin in PBS for
20 min at RT. Non-specific binding sites were blocked
with 5% normal serum (Dako; dilution 1:10 in PBS) for
30 min. Avidin-binding sites were blocked with
Table 1: Sequences of primers used for PCR amplification of 
TLR2 and β-actin.
Human TLR2 Forward, 5'-TCACTGCTTTCAACTGGTAGTTGTG-3'
Reverse, 5'-TCCTTGGAGAGGCTGATGATG-3'
Human β-actin Forward, 5'-GCCAACCGCGAGAAGATG-3'
Reverse, 5'-ACGGCCAGAGGCGTACAG-3'
PCR: polymerase chain reaction
TLR: Toll-like receptorRespiratory Research 2005, 6:100 http://respiratory-research.com/content/6/1/100
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incubation of Avidin D solution (Vector Laboratories,
Burlingame, CA, USA) for 15 min. Thereafter, the sections
were rinsed in PBS (3 × 5 min) before blocking of biotin-
binding sites with biotin blocking solution (Vector) for 15
min. After additional rinsing (PBS; 3 × 5 min) sections
were incubated with the primary antibody overnight at
4°C (in control sections the primary antibody was omit-
ted). The primary antibody was diluted in PBS supple-
mented with 0.25% Triton X and 0.25% bovine serum
albumin. The primary antibodies were: anti-TLR2 (dilu-
tion 1:50), anti-TLR3 (dilution 1:100), anti-TLR4 (dilu-
tion 1:50). All primary antibodies were purchased from
ImmunoKontact, AMS Biotechnology, Oxon, UK. After
overnight incubation with primary antibody, the sections
were rinsed (3 × 5 min in PBS) and incubated with bioti-
nylated secondary antibody (horse anti-mouse IgG1, Vec-
tor, dilution 1:200 or goat anti-rabbit, dilution 1:200) for
45 min at RT. After additional rinsing (3 × 5 min in PBS),
the sections were incubated with alkaline phosphatase-
labeled Streptavidin (dilution 1:200 for 45 min), rinsed
(3 × 5 min in PBS) and alkaline phosphate activity was
developed for 6 min at RT using New Fuchsin (Dako) as
enzyme substrate. Endogenous alkaline phosphatase
activity was inhibited by Levamisol. All sections were
counter-stained with Harris's hematoxylin, coated with
Aqua Perm mounting medium (484975 Life Sci. Interna-
tional), dried overnight and mounted in DPX. Positive
immunoreactivity was identified as bright red precipitate.
For quantification of TLR immunoreactivity, high resolu-
tion digital images were obtained from each biopsy, so
that the entire mucosal area was captured. Occasional
regions where the epithelial lining had been lost due to
mechanical damage (such regions were present to an
equal extent among the different groups) were excluded
from the study. Using an image analysis system (Image-
Pro Plus v4.51, Media Cybernetics, Silver Spring, USA)
and a preset fixed colour threshold value, the number of
positively (i.e. bright red) pixels was automatically calcu-
lated. The immunoreactivity of each TLR was expressed in
relation to the area of mucosal tissue.
Statistics
Statistical analysis was performed using GraphPad Prism
4. All data are expressed as mean ± SEM, and n equals the
number of subjects. For mRNA data, group comparisons
were made between controls and patients outside pollen
season as well as between patients outside and during pol-
len season. For immunohistochemical data, group com-
parisons were made between controls and patients before
allergen challenge as well as between patients before and
after allergen challenge. Mann-Whitney test was used to
determine statistical differences for unpaired comparisons
and Wilcoxon signed rank test was used for paired com-
parisons. P-values less than or equal to 0.05 were consid-
ered statistically significant.
Results
Real-time PCR analysis of total RNA extracted from nasal
biopsies demonstrated the presence of TLR2, TLR3 and
TLR4 as well as β-actin in all samples. The expression of
TLR2 mRNA, in relation to 100,000 molecules of β-actin,
was 78 ± 13 in controls (n = 17), 112 ± 13 in patients out-
side pollen season (n = 19) and 122 ± 27 in patients dur-
ing pollen season (n = 12). The differences seen between
the groups were not statistically significant (Figure 1A).
The expression of TLR3 mRNA was 318 ± 67 in controls (n
= 15), 279 ± 31 in patients outside pollen season (n = 19)
and 473 ± 80 in patients during pollen season (n = 11).
The increase seen during pollen season was statistically
significant (p < 0.05) (Figure 1B). The expression of TLR4
mRNA was 44 ± 7 in controls (n = 14), 55 ± 8 in patients
outside pollen season (n = 19) and 103 ± 28 in patients
during pollen season (n = 11). The apparent seasonal
increase did not reach statistical significance (Figure 1C).
All patients reported an increase in nasal symptoms both
5 and 15 min after allergen challenge (data not shown).
The most intensive immunoreactivity for all three TLRs
was seen within the airway epithelium (Figure 2A–F),
where the staining was foremost distributed to epithelial
cells positioned in the apical region of the epithelium. The
same distribution pattern was observed among healthy
controls and this pattern was not changed by the allergen
challenge. A particularly intense staining was observed in
scattered areas covered by a low-height repair epithelium.
Immunoreactivity for the different TLRs was also seen in a
few scattered intraepithelial leukocytes. For all examined
TLRs, immunoreactivity was also present in scattered sub-
epithelial cells. However, although being distinct from
controls, the staining was generally variably pale and pal-
lid which precluded a proper quantification. The weak
intensity also jeopardized identification of positive cell
types by e.g. double labeling techniques. Hence, a more
tentative identification was made based on morphologi-
cal criteria. In this regard, mast cells were identified as
large granulated and mononuclear cells, granulocytes by
their characteristic polymorph nuclei, lymphocytes as
small mononuclear cells with a circular nucleus sur-
rounded by only a thin rim of cytoplasm. Using these
morphological criteria, TLR2 immunoreactivity could be
observed in mast cells, granulocytes as well as in few scat-
tered large non-granulated mononuclear cells (Figure 3A).
Among the subepithelial TLR3-positive cells, only mast
cells (Figure 3B) and occasional granulocytes were
observed whereas immunoreactivity for TLR4 was present
in mast cells, lymphocytes (Figure 3C), granulocytes and
large non-granulated mononuclear cells (Figure 3D).Respiratory Research 2005, 6:100 http://respiratory-research.com/content/6/1/100
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The total immunoreactivity for TLR2, in relation to the
area of mucosal tissue, was 0.61 ± 0.21 in controls (n = 9),
0.24 ± 0.29 in patients before allergen challenge (n = 11)
and 2.16 ± 0.81 after allergen challenge (n = 11). There
was an increase in TLR2 immunoreactivity after allergen
challenge (p < 0.05; Figure 4A). Immunoreactivity for
TLR3 was 1.39 ± 0.44 in controls (n = 9), 0.64 ± 0.25 in
patients before allergen challenge (n = 11) and 2.22 ±
0.79 in patients after allergen challenge (n = 11). There
was an increase in TLR3 immunoreactivity after allergen
challenge (p = 0.05; Figure 4B). Immunoreactivity for
TLR4 was 0.93 ± 0.40 in controls (n = 9), 0.47 ± 0.32 in
patients before allergen challenge (n = 11) and 2.34 ±
0.80 in patients after allergen challenge (n = 10). There
was an increase in TLR4 immunoreactivity after allergen
challenge (p < 0.05; Figure 4C). 2 or 3 patients out of the
11 had a heightened response to allergen (Figure 4A–C).
These patients were challenged with grass and with the
exception of one patient, these data points all emanated
from different individuals.
Discussion
Real-time PCR demonstrated mRNA expression of TLR2,
TLR3 and TLR4 in biopsies from the inferior turbinate of
all tested subjects. Immunohistochemistry confirmed the
occurrence of the corresponding proteins in the airway
epithelium. Differences were not seen in mRNA content
or in protein expression, when patients with seasonal
allergic rhinitis were examined before pollen season or
before allergen challenge and compared with healthy con-
trols. A significant increase of mRNA for TLR3 was
obtained during pollen season. The protein expression for
all three TLRs increased in the rhinitis patients following
a challenge with relevant pollen, supporting the idea of a
role for TLRs in allergic airway inflammation.
The expression of TLRs has been established in different
cells of the immune system, including dendritic cells,
eosinophils, monocytes, macrophages and neutrophils,
illustrating the role of TLRs in modulating inflammatory
responses [19-21]. However, reports of protein verified
TLR expression in human airways including nasal tissue
are still lacking for most of the TLRs. In the present study,
immunoreactivity for TLR2, TLR3 and TLR4 could be
demonstrated in the apical part of the nasal epithelium.
This is in line with previous findings for TLR2, TLR3 and
TLR4 in cultured epithelial cells [4,14,22,23]. The sites for
a possible TLR expression are known to vary between dif-
ferent cell types, i.e. TLR3 is found exclusively in the intra-
cellular compartments of dendritic cells [24], whereas it
can be found both on the cell surface and in intracellular
parts of human lung fibroblasts [25]. Since TLRs are part
of the first line of defense responding to the presence of
different types of microbes in the airways, it seems reason-
able that these receptors are localized in the apical part of
mRNA expression of TLR2, TLR3 and TLR4 in nasal mucosa Figure 1
mRNA expression of TLR2, TLR3 and TLR4 in nasal 
mucosa. Expression levels of TLR2 (A), TLR3 (B) and TLR4 
(C) in biopsies of nasal mucosa from healthy volunteers (con-
trols), from patients with intermittent allergic rhinitis outside 
pollen season and from patients with symptomatic intermit-
tent allergic rhinitis during pollen season. Levels of mRNA 
were calculated in relation to 100,000 mRNA molecules of 
β-actin. Bold lines represent mean values. Increase in the 
mRNA expression of TLR3 in patients during pollen season 
compared to patients outside pollen season (*p < 0.05).
A
C
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Immunoreactivity of TLR2, TLR3 and TLR4 in nasal mucosa Figure 2
Immunoreactivity of TLR2, TLR3 and TLR4 in nasal mucosa. Immunohistochemical localization of TLR2, TLR3 and 
TLR4 in biopsies of nasal mucosa. Representative pictures of control (A) and TLR-stained (B-F) sections. No immunoreactivity 
was observed in control sections when the primary antibody was omitted (A). In an adjacent section, immunoreactivity for 
TLR3 is seen in the apical part of the epithelial lining and in a few scattered intraepithelial leukocytes (B). Pictures C and D illus-
trate representative staining patterns of TLR2 and TLR4, respectively. Areas with a thin repairing epithelium display a particu-
larly intense staining, TLR3 (E) and TLR4 (F). Scale bars: A, B and D = 85 µm, C = 30 µm, E and F= 50 µm.Respiratory Research 2005, 6:100 http://respiratory-research.com/content/6/1/100
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the epithelial cells, facing the lumen. Expression of TLR4
has previously been described in the nasal mucosa from
both children and adults irrespective of atopy status, and
during control conditions this expression is more marked
among children [17]. Only adults participated in the
present study and it is unlikely that the slight difference in
age between the patients [median age 36 (18–68)] and
controls [median age 27 (16–50)] affected the outcome.
The amount or patterns of inflammatory cells with a pos-
itive staining for TLR2, TLR3 and TLR4 in the submucosa
was limited and did not increase as a result of allergen
challenge. Unfortunately the pallid appearance of the
immunoreactivity in subepithelial cells precluded a
proper identification of the TLR-positive cells (a potential
explanation to the different intensity observed among epi-
thelial and subepithelial cells may simply be that it
reflects a relative higher expression i.e. more receptor mol-
ecules per cell within the epithelium). However, a tenta-
tive identification of subepithelial cells was made based
on classical morphological criteria. Based on these it is
surmised that TLR2 and TLR4 have a rather widespread
Immunoreactivity of TLR2, TLR3 and TLR4 in subepithelial cells Figure 3
Immunoreactivity of TLR2, TLR3 and TLR4 in subepithelial cells. Bright field micrographs exemplifying TLR-positive 
cells in the subepithelial tissue. Granulocyte containing TLR2-like immunoreactivity (A), TLR3-positive mast cell (B), TLR4 
immunoreactivity in lymphocyte-like cells (C) as well as in a large mononuclear cell (D). Scale bars: A, B and D = 10 µm, C = 8 
µm.Respiratory Research 2005, 6:100 http://respiratory-research.com/content/6/1/100
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expression among the immune cells, being present in
mast cells, granulocytes, lymphocytes, and large agranular
mononucleated cells (likely to be macrophages or den-
dritic cells). In contrast, subepithelial TLR3-like immuno-
reactivity was restricted to mast cells and occasional
granulocytes.
The mRNA expression of TLR3 was found to be elevated
among patients with on-going symptomatic allergic rhin-
itis. This is well in line with the increase of the correspond-
ing protein seen following allergen challenge. mRNA for
TLR4 exhibited a similar tendency, however not reaching
statistical significance, whereas no seasonal increase was
seen for TLR2 mRNA. The discrepancy between TLR2 and
TLR4 mRNA on one hand and their corresponding pro-
teins on the other could be explained in several ways. First
of all, we must acknowledge that TLR2, TLR3 and TLR4
appear to be localized mainly in the apical part of the epi-
thelium. mRNA from nasal biopsies is comprised of a het-
erogeneous mix of different cells not only from the
epithelium, but also from the submucosa. An increase in
TLR mRNA expression in the epithelial cells might
therefore be masked by a lack of increase in the submu-
cosal cells. Another explanation might be related to varia-
tions in the mRNA expression between individuals. The
mRNA data were derived from two separate groups of
patients, one sampled before and the other during pollen
season. The protein data were paired, each patient con-
tributed with two biopsies, one before and the other after
allergen challenge, thereby omitting variations between
individuals. Finally, a single allergen challenge differs
from the prolonged allergen exposure seen during pollen
season. It might be that the increase in immunoreactivity
for TLR2, TLR3 and TLR4 seen after allergen challenge
only persists for a limited period of time. If so, the mRNA
expression might, after an initial increase, have decreased
towards normal a few days into the pollen season.
The increased expression of TLR2, TLR3 and TLR4 as a
consequence of allergen exposure is in line with a previ-
ous report demonstrating an increase of TLR2 protein in
chronic middle ear inflammation [26]. The lack of
increase in TLR2 and TLR4 mRNA, discussed above, is in
accordance with another study demonstrating no differ-
ences in the expression of TLR2 and TLR4 when mRNA
from normal turbinates were compared with samples
from patients with chronic sinusitis and/or nasal polyps
[3]. Proteins were not investigated in the latter study. It is
also worth noticing that the inflammation in chronic
sinusitis and nasal polyps is different from the acute
inflammation seen in the nasal epithelium during inter-
mittent allergic rhinitis.
The role of TLRs as a primary part of our microbe defense
system has been shown in several studies, but their
Quantitative immunoreactivity of TLR2, TLR3 and TLR4 in  nasal mucosa Figure 4
Quantitative immunoreactivity of TLR2, TLR3 and 
TLR4 in nasal mucosa. Quantitative analysis of TLR2 (A), 
TLR3 (B) and TLR4 (C) immunostaining in nasal epithelium in 
biopsies from healthy volunteers (controls), from patients 
with intermittent allergic rhinitis before nasal allergen chal-
lenge and from the same patients after allergen challenge. 
TLR immunoreactivity is expressed in relation to the area of 
mucosal tissue. Lines connecting patients before and after 
allergen challenge represent paired data. Increase in the 
immunostaining for TLR2 (*p < 0.05), TLR3 (*p = 0.05) and 
TLR4 (*p < 0.05) after allergen challenge.
A
C
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possible function as mediators in allergy and asthma
remains to be established. Thus, their role as detectors of
pathogens has provided molecular mechanisms to under-
pin the observations leading to the so-called hygiene
hypothesis. This theory proposes that a major source of
microbial, Th1-like, immune provocations has been lost
with the decreased incidence of many infectious diseases
due to vaccinations, the use of antibiotics, and a higher
hygiene standard [27]. The deficiency in Th1-like provoca-
tions leads to Th2-biased immune responses towards
environmental allergens and consequently to an increase
in allergic airway diseases [28,29]. In line with this
hypothesis, it has been shown that children of farmers,
known to have a decreased risk of developing allergies,
expressed higher levels of TLR2 mRNA in blood compared
to children of non-farmers. The expression of TLR4 was
not altered in farmers' children, but the level of the co-fac-
tor CD14 was markedly increased, indicating a change in
receptor mediated signaling activity [29]. However, once
the allergic airway inflammation has been established,
bacterial and viral infections may be as relevant as aller-
gens in inducing hyperreactive responses [30-33].
Conclusion
An up-regulation of TLR2, TLR3 and TLR4 in the nasal
mucosa of patients with symptomatic allergic rhinitis sup-
ports the idea of a role for TLRs in allergic inflammation.
In several airway model systems, stimulation of TLRs
results in changes in the production of effector molecules,
such as cytokines and chemokines, thereby affecting and
further upgrading the airway inflammation [4,14-17]. It is
also well known that viral as well as bacterial infections
can worsen the symptoms of allergic rhinitis and trigger
exacerbations of asthma [6]. Thus, an increase in the
amount of TLRs present in the apical part of the epithe-
lium might induce a hyperreactive response to bacteria
and viruses in patients with seasonal allergic rhinitis.
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